JP2023539047A5 - - Google Patents
Info
- Publication number
- JP2023539047A5 JP2023539047A5 JP2023509698A JP2023509698A JP2023539047A5 JP 2023539047 A5 JP2023539047 A5 JP 2023539047A5 JP 2023509698 A JP2023509698 A JP 2023509698A JP 2023509698 A JP2023509698 A JP 2023509698A JP 2023539047 A5 JP2023539047 A5 JP 2023539047A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- patients weighing
- day
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025204019A JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065107P | 2020-08-13 | 2020-08-13 | |
| US63/065,107 | 2020-08-13 | ||
| PCT/US2021/045823 WO2022036151A1 (en) | 2020-08-13 | 2021-08-12 | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204019A Division JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539047A JP2023539047A (ja) | 2023-09-13 |
| JP2023539047A5 true JP2023539047A5 (https=) | 2024-08-22 |
| JP7821160B2 JP7821160B2 (ja) | 2026-02-26 |
Family
ID=77655658
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509698A Active JP7821160B2 (ja) | 2020-08-13 | 2021-08-12 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
| JP2025204019A Pending JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204019A Pending JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209071A1 (https=) |
| EP (1) | EP4196161A1 (https=) |
| JP (2) | JP7821160B2 (https=) |
| KR (1) | KR20230047179A (https=) |
| CN (1) | CN116249550A (https=) |
| AU (1) | AU2021326526B2 (https=) |
| CA (1) | CA3173007A1 (https=) |
| IL (1) | IL300115A (https=) |
| MX (1) | MX2023001702A (https=) |
| WO (1) | WO2022036151A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4583911A1 (en) | 2022-09-06 | 2025-07-16 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP6654137B2 (ja) * | 2013-09-16 | 2020-02-26 | チルドレンズ ホスピタル メディカル センター | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CA3024618A1 (en) * | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| CN118512588A (zh) * | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| EP4135837A1 (en) * | 2020-04-16 | 2023-02-22 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
-
2021
- 2021-08-12 WO PCT/US2021/045823 patent/WO2022036151A1/en not_active Ceased
- 2021-08-12 KR KR1020237008325A patent/KR20230047179A/ko active Pending
- 2021-08-12 CA CA3173007A patent/CA3173007A1/en active Pending
- 2021-08-12 JP JP2023509698A patent/JP7821160B2/ja active Active
- 2021-08-12 AU AU2021326526A patent/AU2021326526B2/en active Active
- 2021-08-12 EP EP21766299.8A patent/EP4196161A1/en active Pending
- 2021-08-12 US US18/018,936 patent/US20240209071A1/en active Pending
- 2021-08-12 MX MX2023001702A patent/MX2023001702A/es unknown
- 2021-08-12 IL IL300115A patent/IL300115A/en unknown
- 2021-08-12 CN CN202180050198.2A patent/CN116249550A/zh active Pending
-
2025
- 2025-11-26 JP JP2025204019A patent/JP2026026191A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022202649B2 (en) | Antibody formulations and methods | |
| JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
| JP2021501134A5 (https=) | ||
| JP2021526534A5 (https=) | ||
| US9243060B2 (en) | Humanized anti-factor C3b antibodies and uses thereof | |
| JP2021525718A5 (https=) | ||
| JP2026053516A (ja) | バイオ医薬組成物 | |
| DK166763B1 (da) | Immunoglobulin-g-holdig fraktion | |
| JP2023533030A5 (https=) | ||
| JP2019507107A (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用 | |
| JP6105146B2 (ja) | Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体 | |
| JP7788281B2 (ja) | 可溶性補体受容体１型変異体コンジュゲートおよびその使用 | |
| EA014025B1 (ru) | Композиции антитела против cd3 | |
| JP2023539047A5 (https=) | ||
| JP2003519619A (ja) | 免疫修飾活性を有する新規Ｉｇ断片 | |
| EP4501965A1 (en) | Antibody, fusion protein and use thereof | |
| TW202216735A (zh) | 製備包含人血漿來源的免疫球蛋白ｍ之組合物的方法及儲存穩定的液體組合物 | |
| KR20110128271A (ko) | Ａｂｏ식 혈액형과 관련한 모-태아 간 부적합에 의해 야기된 신생아 황달 치료용 항-ａ 및 항-ｂ가 대폭 감소된 면역 글로불린 ｇ(면역 글로불린 ｇ) 농축물의 용도 | |
| JP4339405B2 (ja) | 予防・治療剤 | |
| JP2024540480A5 (https=) | ||
| Kato et al. | Rapid deterioration of the renal function caused by the coexistence of intratubular amyloidosis and myeloma cast nephropathy | |
| US20230173155A1 (en) | Dialysis system for treating sepsis | |
| KR20230142834A (ko) | 항-cd38 항체 및 이의 용도 | |
| CN111704670B (zh) | 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法 | |
| JPH0585529B2 (https=) |